THESYST ACS ERGO (Source: Asahi Kasei)
Düsseldorf, Tokyo and New York – April 30, 2024 – Generating cutting-edge therapeutics requires precision, safety, and efficiency from manufacturing equipment. The next generation of oligo manufacturing, the process of producing short sequences of nucleotides (building blocks of DNA or RNA), innovation from Asahi Kasei Bioprocess (AKB), the THESYS™ ACS ERGO synthesis column, will be on display and demonstrated at Booth 213 at TIDES USA 2024 from May 14th to 17th at the Hynes Convention Center in Boston. This new synthesis column offers drastically reduced changeover time between batches while maintaining user safety and product quality.
Following the success of AKB“s DAC ERGO™, a liquid chromatography column, the company has continued advancing column technology with the THESYS™ ACS ERGO. The THESYS ACS ERGO is designed for oligonucleotide synthesis and includes an operator-friendly design to facilitate a smooth and safe changeover between runs. It provides the same reliable high-performance as AKB“s other synthesis columns but is uniquely engineered to reduce inefficiencies between batches – with upwards of an hour of time savings as well as projected labor reduction.
The time-saving features of the THESYS™ ACS ERGO are achieved by eliminating the use of threaded bolts in the changeover and maintenance process, which can be tedious and time-consuming to remove between runs. AKB has ergonomically designed the THESYS™ ACS ERGO for faster changeover without cost to safety, which improves customer efficiency while maintaining operator safety and product reliability. „Our new, bolt-free design is unique to the column market and makes unpacking and cleaning far less time-consuming,“ said Chris Rombach, Executive Vice President at Asahi Kasei Bioprocess America (AKBA). „Every feature of the ACS ERGO has been considered, with greater productivity for manufacturers and operator safety as the top priorities.“
THESYS™ ACS includes an innovative I-bar format that makes removing the top of the column more efficient and a unique frame with an integrated gearbox and wheel to facilitate smooth, safe unpacking and cleaning. Furthermore, the column has a minimized footprint to seamlessly integrate into the manufacturing floor. In addition to its booth at the event, AKB will host a „Spotlight Presentation“ on May 16 at 12:20 p.m. in room 302 about the oligo manufacturing process. Dr. Tom Krebstakies, Sales Manager for Europe and Asia at AKB, will speak about innovations from synthesis through concentration and the applicable equipment considerations for effective technical implementation.
Attendees are invited to visit AKB at Booth 213 to explore new products, witness live demos, and learn more about how AKB“s innovations make manufacturing therapeutics easier. Learn more about how AKB helps oligo process engineers quickly improve throughput, efficiency, and costs.
About Asahi Kasei Bioprocess
The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world. Built with pride, built with quality, built to exceed expectations. „Built for You.“ For more information, please visit
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its founding in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its Material sector, comprised of Environmental Solutions, Mobility & Industrial, and Life Innovation, includes a wide array of products from battery separators and biodegradable textiles to engineering plastics and sound solutions. For more information, visit
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon-neutral society by 2050. To learn more, visit sustainability/
Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
Asahi Kasei Bioprocess Contact:
Asahi Kasei Bioprocess America, Inc.
Steve Foy
Image source: Asahi Kasei
About the Asahi Kasei Corporation
Asahi Kasei Corporation is a globally active diversified technology company with operations in the Material, Homes, and Health Care business sectors. The Material sector encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes sector provides housing and construction materials to the Japanese market. The Health Care sector includes pharmaceuticals, medical devices, and acute critical care devices and systems. With more than 46,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries and achieved sales of 20 billion euros (2.726 billion yen) in the fiscal year 2022 (April 1, 2022 – March 31, 2023).
Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world. For more information, visit
www.asahi-kasei.eu, www.asahi-kasei.com and sustainability/
Company contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Fringsstrasse 17
40221 Düsseldorf
+49 (0)211 3399-2058
Press contact
financial relations GmbH
Henning Yes
Louisenstraße 97
61348 Bad Homburg
+49 (0) 6172 27159 12